Trial Profile

A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lifirafenib (Primary) ; Mirdametinib (Primary)
Indications Colorectal cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors BeiGene

14 Mar 2025 Status changed from recruiting to active, no longer recruiting.
05 Jun 2023 Phase of the trial is changed from phase 1/2 to phase 1. Number of treatment arms have been reduced from 4 to 2, by the removal of Experimental: Part B: Group 1 and Experimental: Part B: Group 3 arms.
05 Jun 2023 Planned End Date changed from 29 Apr 2024 to 28 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com